The influence of the COVID-19 pandemic on stage migration and management of patients presenting to a penile cancer supra-network
BAUS ePoster online library. Lingamanaicker V. 06/21/21; 319084; p4-6
Disclosure(s): Yes
Vidhya Lingamanaicker
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
Introduction: COVID-19 has had potential impact on presentation and outcome of patients to cancer services. The objective of this study was to analyse pandemic effects on patients with penile SCC by comparison with previous years within a stable 10 million population referral base.
Patients and Methods: All patients referred to the penile supranetwork MDT (snMDT), 1st January 2020 to 31st December 2020 identified (COVID-19 Group A). Prospectively collated data from previous 3 years (2017-19) referrals analysed to create a service year mean dataset (Non-COVID-19 Group B). Variables compared: (i) overall demographics, (ii) pathological stage (TNM 8), (iii) time from presentation to first treatment. Chi-squared test to evaluate the pathological stage (TNM 8) and Mann-Whitney U Test to assess time from presentation to first treatment.
Results: Group A, 123 new referrals. Group B mean referrals 129 (118 - 147). Primary stage Group A, 45.4% pT1, 30.2% pT2, 24.4% pT3/pT4 vs Group B, 48.6% pT1, 38.2% pT2, 13.2% pT3/pT4 (p=0.01). Nodal stage pN0 Group A 62% vs 70% Group B, (NS p = 0.08). Median time (days) presentation to first treatment Group A, 22 (IQ 15 - 36) vs Group B, 26 (13 – 36.5).
Conclusion: No. of referrals were statistically similar in COVID-19 and Non-COVID-19 years and managed within similar time frame. However, there was a statistically higher pT disease stage in the COVID-19 group but no significant difference in pN stage (although trend towards higher nodal stage). Data is not yet mature to determine an effect on cancer specific survival.
Patients and Methods: All patients referred to the penile supranetwork MDT (snMDT), 1st January 2020 to 31st December 2020 identified (COVID-19 Group A). Prospectively collated data from previous 3 years (2017-19) referrals analysed to create a service year mean dataset (Non-COVID-19 Group B). Variables compared: (i) overall demographics, (ii) pathological stage (TNM 8), (iii) time from presentation to first treatment. Chi-squared test to evaluate the pathological stage (TNM 8) and Mann-Whitney U Test to assess time from presentation to first treatment.
Results: Group A, 123 new referrals. Group B mean referrals 129 (118 - 147). Primary stage Group A, 45.4% pT1, 30.2% pT2, 24.4% pT3/pT4 vs Group B, 48.6% pT1, 38.2% pT2, 13.2% pT3/pT4 (p=0.01). Nodal stage pN0 Group A 62% vs 70% Group B, (NS p = 0.08). Median time (days) presentation to first treatment Group A, 22 (IQ 15 - 36) vs Group B, 26 (13 – 36.5).
Conclusion: No. of referrals were statistically similar in COVID-19 and Non-COVID-19 years and managed within similar time frame. However, there was a statistically higher pT disease stage in the COVID-19 group but no significant difference in pN stage (although trend towards higher nodal stage). Data is not yet mature to determine an effect on cancer specific survival.
Introduction: COVID-19 has had potential impact on presentation and outcome of patients to cancer services. The objective of this study was to analyse pandemic effects on patients with penile SCC by comparison with previous years within a stable 10 million population referral base.
Patients and Methods: All patients referred to the penile supranetwork MDT (snMDT), 1st January 2020 to 31st December 2020 identified (COVID-19 Group A). Prospectively collated data from previous 3 years (2017-19) referrals analysed to create a service year mean dataset (Non-COVID-19 Group B). Variables compared: (i) overall demographics, (ii) pathological stage (TNM 8), (iii) time from presentation to first treatment. Chi-squared test to evaluate the pathological stage (TNM 8) and Mann-Whitney U Test to assess time from presentation to first treatment.
Results: Group A, 123 new referrals. Group B mean referrals 129 (118 - 147). Primary stage Group A, 45.4% pT1, 30.2% pT2, 24.4% pT3/pT4 vs Group B, 48.6% pT1, 38.2% pT2, 13.2% pT3/pT4 (p=0.01). Nodal stage pN0 Group A 62% vs 70% Group B, (NS p = 0.08). Median time (days) presentation to first treatment Group A, 22 (IQ 15 - 36) vs Group B, 26 (13 – 36.5).
Conclusion: No. of referrals were statistically similar in COVID-19 and Non-COVID-19 years and managed within similar time frame. However, there was a statistically higher pT disease stage in the COVID-19 group but no significant difference in pN stage (although trend towards higher nodal stage). Data is not yet mature to determine an effect on cancer specific survival.
Patients and Methods: All patients referred to the penile supranetwork MDT (snMDT), 1st January 2020 to 31st December 2020 identified (COVID-19 Group A). Prospectively collated data from previous 3 years (2017-19) referrals analysed to create a service year mean dataset (Non-COVID-19 Group B). Variables compared: (i) overall demographics, (ii) pathological stage (TNM 8), (iii) time from presentation to first treatment. Chi-squared test to evaluate the pathological stage (TNM 8) and Mann-Whitney U Test to assess time from presentation to first treatment.
Results: Group A, 123 new referrals. Group B mean referrals 129 (118 - 147). Primary stage Group A, 45.4% pT1, 30.2% pT2, 24.4% pT3/pT4 vs Group B, 48.6% pT1, 38.2% pT2, 13.2% pT3/pT4 (p=0.01). Nodal stage pN0 Group A 62% vs 70% Group B, (NS p = 0.08). Median time (days) presentation to first treatment Group A, 22 (IQ 15 - 36) vs Group B, 26 (13 – 36.5).
Conclusion: No. of referrals were statistically similar in COVID-19 and Non-COVID-19 years and managed within similar time frame. However, there was a statistically higher pT disease stage in the COVID-19 group but no significant difference in pN stage (although trend towards higher nodal stage). Data is not yet mature to determine an effect on cancer specific survival.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}